Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Clinical and Translational Allergy

Figure 2

From: Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study

Figure 2

Patient disposition. Patients were randomized to receive either placebo or 300IR sublingual solution of birch allergen extract initiated approximately 4 months before the birch pollen season and continued through it. Patients were treated discontinuously for two consecutive years.

Back to article page